Diana M. Brainard

Open Data Institute — United Kingdom

Medicine · Health Sciences

75h-index26.7kcitations309works3.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatitis C virus research(222), HIV/AIDS drug development and treatment(118), Liver Disease Diagnosis and Treatment(109), Hepatitis B Virus Studies(105), HIV Research and Treatment(29)

Publications306 total

Inference of Host–Pathogen Interaction Matrices from Genome-Wide Polymorphism Data
Molecular Biology and Evolution·2024· 3 citedOpen Access
Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection
JHEP Reports·2023· 12 citedOpen Access
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials
Queen Mary Research Online (Queen Mary University of London)·2023Open Access
S1189 Safety and Efficacy of Oral TLR8 Agonist, Selgantolimod, in Viremic Adult Patients With Chronic Hepatitis B
The American Journal of Gastroenterology·2022
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
New England Journal of Medicine·2022· 270 citedOpen Access
Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.
PubMed·2021· 2 citedOpen Access
Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure
Nature Communications·2021· 22 citedOpen Access
Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial
Intensive Care Medicine·2021· 124 citedOpen Access
P-6 SOFOSBUVIR CONTAINING REGIMENS ARE SAFE AND EFFECTIVE IN ADOLESCENTS WITH CHRONIC HEPATITIS C INFECTION
Annals of Hepatology·2021Open Access
IDDF2021-ABS-0078 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with moderate or severe renal impairment, or with end-stage renal disease (ESRD)
2021Open Access
Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials
JAIDS Journal of Acquired Immune Deficiency Syndromes·2021· 11 citedOpen Access
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial
The Lancet Child & Adolescent Health·2021· 20 cited
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet HIV·2021· 88 citedOpen Access
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy
Science Translational Medicine·2021· 72 cited
Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality
Open Forum Infectious Diseases·2021· 45 citedOpen Access
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study
JAIDS Journal of Acquired Immune Deficiency Syndromes·2021· 39 citedOpen Access
Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study
˜The œLancet. Gastroenterology & hepatology·2021· 95 citedOpen Access
Compassionate Use of Remdesivir in Children With Severe COVID-19
PEDIATRICS·2021· 103 cited
Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants
Journal of Antimicrobial Chemotherapy·2021· 14 citedOpen Access
Correction to: Ledipasvir–Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection
Clinical Drug Investigation·2021Open Access
page 1 of 16Next →

Frequent Co-authors

John G. McHutchison(28), Hadas Dvory‐Sobol(13), Evguenia S. Svarovskaia(12), Anu Osinusi(11), Robert H. Hyland(11), Eric Lawitz(10), William T. Symonds(10), Edward Gane(10), John McNally(9), Ira M. Jacobson(8), G. Mani Subramanian(8), Hongmei Mo(8), Peter Ruane(7), Kosh Agarwal(6), Mark Sulkowski(6), Benedetta Massetto(6), Lijie Zhong(5), Anuj Gaggar(5), Alessandra Mangia(5), K. Rajender Reddy(5)